CORMORANT ASSET MANAGEMENT LP
Q1 2026 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001583977
· CRD 167820
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2013
$2.0B Reported Value Total
CORMORANT ASSET MANAGEMENT, LP reports 16 total accounts under management (AUM). There are 16 discretionary accounts valued at $3,838,575,938, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
7 funds
· $3.8B gross asset value
Hedge Fund: $2.2B · Private Equity Fund: $1.6B
Source: Form ADV filed 2026-05-27
Reported value
$2.0B
Quarter over quarter
-1.5%
Holdings
46
Top-10 concentration
59.1%
Filing Structure
Reports holdings for
- Chen Bihua · File #028-15950 · since Q4 2013
Key People
Form ADV owners & control persons
Bihua Chen
MANAGING MEMBER & CHIEF EXECUTIVE OFFICER
Nebojsa Obradovic
CHIEF COMPLIANCE OFFICER & GENERAL COUNSEL
Caleb Jonathan Tripp
CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $2.0B |
| Positions | 46 |
| Change in reported value | -7.9% |
| New positions | 17 |
| Exited positions | 3 |
| Position turnover | 40.8% |
| Top-10 concentration | 59.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
50 | $2.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
46 | $2.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
32 | $2.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
36 | $1.4B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
42 | $1.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
42 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
48 | $1.8B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
45 | $1.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
47 | $1.7B |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $2.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
47 | $2.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
49 | $1.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
61 | $1.8B |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $1.5B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
72 | $1.5B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
72 | $1.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
79 | $1.3B |
|
Q1 2022 13F
Filed May 16, 2022
|
77 | $1.3B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
78 | $1.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
88 | $2.5B |
31 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PRAX PRAXIS PRECISION MEDICINES I | $285.3M | 14.33% |
| 2 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | $160.0M | 8.04% |
| 3 | EYPT EYEPOINT INC | $106.5M | 5.35% |
| 4 | EWTX EDGEWISE THERAPEUTICS INC | $102.7M | 5.16% |
| 5 | ERAS ERASCA INC | $93.8M | 4.71% |
| 6 | RAPP RAPPORT THERAPEUTICS INC | $92.5M | 4.65% |
| 7 | ALMS ALUMIS INC | $87.0M | 4.37% |
| 8 | ABVX ABIVAX SA | $84.6M | 4.25% |
| 9 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $83.5M | 4.19% |
| 10 | DNTH DIANTHUS THERAPEUTICS INC | $79.7M | 4.0% |
| 11 | DRUG BRIGHT MINDS BIOSCIENCES INC | $77.3M | 3.88% |
| 12 | BBIO BRIDGEBIO PHARMA INC | $63.1M | 3.17% |
| 13 | OLMA OLEMA PHARMACEUTICALS INC | $58.1M | 2.92% |
| 14 | BIOA BIOAGE LABS INC | $50.6M | 2.54% |
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | $41.7M | 2.09% |
| 16 | GLTO DAMORA THERAPEUTICS INC | $39.5M | 1.98% |
| 17 | MBX MBX BIOSCIENCES INC | $33.4M | 1.68% |
| 18 | INSM INSMED INC | $31.1M | 1.56% |
| 19 | NAMS NEWAMSTERDAM PHARMA COMPANY | $30.4M | 1.53% |
| 20 | TNGX TANGO THERAPEUTICS INC | $29.8M | 1.5% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.